3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Neoplasms
3
Breast Neoplasms
3
Sarcoma
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thymus Neoplasms
1
Sex Cord-Gonadal Stromal Tumors
1
Sarcoma, Synovial
1
Prostatic Neoplasms
1
Peritoneal Neoplasms
1
Neoplasms, Germ Cell and Embryonal
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mesothelioma
1
Meningioma
1
Lymphoma, Large B-Cell, Diffuse
1
Liposarcoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Glioma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Fatigue
1
Dermatofibrosarcoma
1
Cardiovascular Diseases
1
Carcinoma, Squamous Cell
1
Brain Neoplasms
1
Interventions
Doxorubicin
5
pembrolizumab
4
Specimen Handling
4
Radiotherapy
4
Radiation
4
Nivolumab
4
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
CTLA-4 Antigen
3
Biopsy
3
cabozantinib
2
Ifosfamide
2
tremelimumab
1
talimogene laherparepvec
1
regorafenib
1
peposertib
1
pazopanib
1
olaratumab
1
liposomal doxorubicin
1
futibatinib
1
fludarabine
1
eribulin
1
durvalumab
1
avelumab
1
aldesleukin
1
X-Rays
1
Trabectedin
1
Standard of Care
1
Quality of Life
1
Injections
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Histiocytoma, Malignant Fibrous
×
Quality of Life
×
1 year
×
Clear all
NCT07169344
2026-01-28
PROSARC-1
Oslo University Hospital
Phase 2
Recruiting
110 enrolled